by The Rising Demand For EYLEA Drug Industry Treatment Options
EYLEA (Aflibercept), developed by Regeneron Pharmaceuticals Inc. and Bayer AG, has revolutionized the treatment of various eye diseases since its market approval in 2011. As one of the leading drugs used in the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), the demand for EYLEA continues to rise globally.
Wet AMD remains the leading cause of blindness in developed countries affecting millions worldwide. EYLEA therapy has become the standard of care for treating this blinding eye condition due to its highly effective results in improving and maintaining vision. Numerous clinical trials have consistently demonstrated EYLEA’s ability to increase the number of patients who gain three or more lines of visual acuity compared to other anti-VEGF treatments.
Growing Diabetic Population Drives Increased Use Of EYLEA Drug Industry
Along with wet AMD, DME is another major driver of the global EYLEA Drug market. As the prevalence of diabetes continues to rise at an alarming rate, more patients are developing DME – a vision-threatening complication of diabetes caused by leaking blood vessels in the eye. EYLEA has proven to be an effective treatment option for DME, significantly improving vision and reducing the need for laser treatment. Ongoing clinical research is further strengthening EYLEA’s role in the management of DME.
Market performance in key regions
The US market accounts for the lion’s share of global EYLEA sales due to the high prevalence of wet AMD among the aging American population. EYLEA continues maintaining its leading market position in the US, outselling other anti-VEGF drugs. Sales in Japan are also strong supported by the drug’s increasing uptake in retinal diseases.
In Europe, EYLEA sales are rising steadily across major markets like Germany, France, Italy, and the UK. However, availability and reimbursement issues remain challenges in some smaller European countries. The approval and commercialization of EYLEA in major Asian markets like China and India present enormous future growth prospects as the burden of retinal diseases grows in the region.
Overall, global sales of EYLEA have more than doubled since 2017, crossing the $7 billion mark in 2020. Analysts project this positive trajectory to continue over the next five years, driven mainly by expanded approvals into new indications and increased adoption in developing countries.
Label Expansion Opens Doors For New Patient Populations
One key factor contributing to the robust performance of EYLEA in the market has been its label expansion into additional retinal conditions over the past years. In 2017, the drug was approved for the treatment of macular edema following RVO, enabling its use in more patients afflicted by this vision-threatening eye disorder.
Obtaining this new approval helped increase EYLEA’s eligible patient population size significantly. Ongoing clinical research is exploring EYLEA’s potential for treating other retinal vascular diseases like polypoidal choroidal vasculopathy, central retinal vein occlusion, and proliferative diabetic retinopathy. Any future approvals in these indications would further bolster the global demand for EYLEA treatment
Pricing And Biosimilar Competition
While EYLEA dominates global anti-VEGF drug sales, pricing pressure and biosimilar competition pose threats that may dampen its revenue growth prospects over time. EYLEA’s list price in the US is among the highest for biologics, raising concerns over affordability and access especially with an increasing number of retinal patients.
However, aggressive rebating strategies have helped maintain EYLEA’s market position so far against cheaper alternatives. The expected approval and launch of EYLEA biosimilars could introduce more treatment options but may also intensify price competition. Regeneron is thus working on extensive patent protection and a strategic pricing framework to maximize the market longevity of its blockbuster drug.
Overall, the global EYLEA drug market is projected to maintain strong growth momentum in the coming years supported by rising disease prevalence, label expansions, and increasing adoption worldwide. However, affordability challenges, competition from biosimilars, and other pipeline assets could impact EYLEA’s revenue trajectory going forward. Ongoing research and strategic pricing maneuvers will be crucial for the drug to retain its leadership position over the long term.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
